Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 7/20 | 1.00 |
| ▸ | PSMB5 | P28074 | 6/20 | 1.00 |
| ▸ | ESR1 | P03372 | 6/20 | 1.00 |
| ▸ | PSMB2 | P49721 | 3/20 | 1.00 |
| ▸ | PDE1A | P54750 | 9/20 | 0.89 |
| ▸ | PDE1B | Q01064 | 9/20 | 0.89 |
| ▸ | PDE1C | Q14123 | 9/20 | 0.89 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30902018 | 1.00 | PSMB1 (1.00) | PSMB1PSMB5ESR1PSMB2PDE1A | |
| SCHEMBL7650156 | 1.00 | PSMB1 (1.00) | PSMB1PSMB5ESR1PSMB2PDE1A | |
| SCHEMBL29822053 | 1.00 | PSMB1 (1.00) | PSMB1PSMB5ESR1PSMB2PDE1A | |
| SCHEMBL15648408 | 1.00 | PSMB1 (1.00) | PSMB1PSMB5ESR1PSMB2PDE1A | |
| SCHEMBL24505428 | 0.95 | ESR1 (0.91) | PSMB1PSMB5ESR1PSMB2PDE1A | |
| SCHEMBL7807876 | 0.95 | ESR1 (0.91) | PSMB1PSMB5ESR1PSMB2PDE1A | |
| SCHEMBL17151967 | 0.95 | ESR1 (0.91) | PSMB1PSMB5ESR1PSMB2PDE1A | |
| SCHEMBL23266947 | 0.95 | ESR1 (0.90) | PSMB1PSMB5ESR1PSMB2PDE1A | |
| Idoxifene SCHEMBL19217 | 0.94 | PDE1A (1.00) | PSMB1PSMB5ESR1PSMB2PDE1A | |
| Idoxifene SCHEMBL3774574 | 0.94 | PDE1A (1.00) | PSMB1PSMB5ESR1PSMB2PDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6489481-B1 | COMPOUNDS USED FOR TREATMENT AND/OR PREVENTION OF NEURONAL APOPTOSIS AND/OR EXCITOTOXICITY RELATED NEUROLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2002-12-03 | — | — | US | disclosed |
| EP-1127045-A2 | USE OF TRIPHENYLBUTENE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | AstraZeneca AB (SE) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025767-A2 | USE OF TRIPHENYLBUTENE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2000-05-11 | — | — | WO | disclosed |